JP2021531239A - ロダニン誘導体を含むaidsの予防または治療用薬学組成物 - Google Patents
ロダニン誘導体を含むaidsの予防または治療用薬学組成物 Download PDFInfo
- Publication number
- JP2021531239A JP2021531239A JP2020564362A JP2020564362A JP2021531239A JP 2021531239 A JP2021531239 A JP 2021531239A JP 2020564362 A JP2020564362 A JP 2020564362A JP 2020564362 A JP2020564362 A JP 2020564362A JP 2021531239 A JP2021531239 A JP 2021531239A
- Authority
- JP
- Japan
- Prior art keywords
- avi
- hiv
- reverse transcriptase
- virus
- nucleoside reverse
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 66
- 208000030507 AIDS Diseases 0.000 title claims abstract description 22
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 8
- 230000002265 prevention Effects 0.000 title claims abstract description 8
- KIWUVOGUEXMXSV-UHFFFAOYSA-N rhodanine Chemical class O=C1CSC(=S)N1 KIWUVOGUEXMXSV-UHFFFAOYSA-N 0.000 title abstract description 8
- 230000000694 effects Effects 0.000 claims abstract description 57
- 239000000203 mixture Substances 0.000 claims abstract description 51
- 150000001875 compounds Chemical class 0.000 claims abstract description 46
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 claims abstract description 41
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims abstract description 40
- 230000036436 anti-hiv Effects 0.000 claims abstract description 29
- 241000700605 Viruses Species 0.000 claims description 97
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims description 57
- 229960004556 tenofovir Drugs 0.000 claims description 53
- 208000015181 infectious disease Diseases 0.000 claims description 37
- 150000003839 salts Chemical class 0.000 claims description 20
- 239000000126 substance Substances 0.000 claims description 15
- 230000002458 infectious effect Effects 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 229960002555 zidovudine Drugs 0.000 claims description 13
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims description 13
- 229960004748 abacavir Drugs 0.000 claims description 9
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical group C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 claims description 9
- 230000002829 reductive effect Effects 0.000 claims description 9
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 claims description 7
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 claims description 6
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 claims description 5
- 229960000366 emtricitabine Drugs 0.000 claims description 5
- 230000007423 decrease Effects 0.000 claims description 4
- -1 ramibdin (3TC) Chemical compound 0.000 claims 3
- 230000002195 synergetic effect Effects 0.000 abstract description 37
- 231100000419 toxicity Toxicity 0.000 abstract description 6
- 230000001988 toxicity Effects 0.000 abstract description 6
- 239000003795 chemical substances by application Substances 0.000 abstract description 5
- 230000001603 reducing effect Effects 0.000 abstract description 4
- 239000002131 composite material Substances 0.000 abstract 1
- 238000010586 diagram Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 85
- 230000000840 anti-viral effect Effects 0.000 description 42
- 241000725303 Human immunodeficiency virus Species 0.000 description 35
- 231100000135 cytotoxicity Toxicity 0.000 description 24
- 230000003013 cytotoxicity Effects 0.000 description 24
- 239000003814 drug Substances 0.000 description 22
- 238000012790 confirmation Methods 0.000 description 17
- 230000002401 inhibitory effect Effects 0.000 description 17
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 13
- 229940124597 therapeutic agent Drugs 0.000 description 13
- 239000003112 inhibitor Substances 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 238000012286 ELISA Assay Methods 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 6
- 238000011002 quantification Methods 0.000 description 6
- 238000011284 combination treatment Methods 0.000 description 5
- 229960001627 lamivudine Drugs 0.000 description 5
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 5
- 239000002777 nucleoside Substances 0.000 description 5
- 150000003833 nucleoside derivatives Chemical class 0.000 description 5
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- 238000004020 luminiscence type Methods 0.000 description 4
- 229960004693 tenofovir disoproxil fumarate Drugs 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 101150066002 GFP gene Proteins 0.000 description 3
- GLWHPRRGGYLLRV-XLPZGREQSA-N [[(2s,3s,5r)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical group O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](N=[N+]=[N-])C1 GLWHPRRGGYLLRV-XLPZGREQSA-N 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 229940014461 combivir Drugs 0.000 description 3
- 231100000263 cytotoxicity test Toxicity 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000007721 medicinal effect Effects 0.000 description 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 3
- 238000004445 quantitative analysis Methods 0.000 description 3
- 230000008791 toxic response Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000007935 oral tablet Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000002407 ATP formation Effects 0.000 description 1
- YCIPQJTZJGUXND-UHFFFAOYSA-N Aglaia odorata Alkaloid Natural products C1=CC(OC)=CC=C1C1(C(C=2C(=O)N3CCCC3=NC=22)C=3C=CC=CC=3)C2(O)C2=C(OC)C=C(OC)C=C2O1 YCIPQJTZJGUXND-UHFFFAOYSA-N 0.000 description 1
- 229940127399 DNA Polymerase Inhibitors Drugs 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 208000016621 Hearing disease Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 238000002832 anti-viral assay Methods 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000002850 integrase inhibitor Substances 0.000 description 1
- 229940124524 integrase inhibitor Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 229960001203 stavudine Drugs 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
MT4細胞(T細胞株の一種)は、10%FBSと10%抗生剤ペニシリン、ストレプトマイシンが含まれたRPMIで培養された。細胞は、37℃、5%CO2の加湿された恒温器で2日ごとに継代培養された。
感染に用いられたすべてのウイルスは、GFP遺伝子を含むNL43由来のHIV−1である。ウイルスの遺伝子にGFP遺伝子を再び組み合わせてGFP発現率がウイルス感染の程度を示すことができる。抗ウイルスの効力の確認のためにヒト由来のT細胞株であるMT4細胞を使用した。MT4細胞を1×105cell/wellの密度で48wellプレートに接種し、HIV−1p24 0.5ngに該当する量のHIV−1で感染させた。感染と同時に効能を確認する混合物が処理された。混合物は、AVI−CO−004にAZT、3TC、TenofovirまたはFTCをそれぞれ混合して準備した。感染3日後に蛍光顕微鏡でGFP蛍光の発現を観察することにより、ウイルスの増殖の程度を確認し、ウイルスの上澄み液を集めて細胞残渣を除去した後に分析した。ウイルスの生成量は、p24 ELISA assayで定量確認した。
AVI−CO−004及びヌクレオシド逆転写酵素阻害剤の併用処理による相乗的HIV抑制能を確認するため、まず、AVI−CO−004単独処理時の抗ウイルスの効力を確認した。
本実験では、AVI−CO−004とAZTを混合した混合物の抗ウイルスの効力を確認した。まず、各100,000個のMT4細胞を48wellプレートに接種してHIV−1p24 0.5ngに該当する量のHIV−1で感染させた。表記された濃度でAVI−CO−004とAZTの混合物を処理し、4日後、p24 ELISA assayで生成されたウイルス量の定量を確認した。
本実験では、AVI−CO−004と3TCを混合した混合物の抗ウイルスの効力を確認した。まず、各100,000個のMT4細胞を48wellプレートに接種してHIV−1p24 0.5ngに該当する量のHIV−1で感染させた。表記された濃度でAVI−CO−004とAZTの混合物を処理し、4日後、p24 ELISA assayで生成されたウイルス量の定量を確認した。
本実験では、AVI−CO−004とTFVを混合した混合物の抗ウイルスの効力を確認した。まず、各100,000個のMT4細胞を48wellプレートに接種してHIV−1p24 0.5ngに該当する量のHIV−1で感染させた。表記された濃度でAVI−CO−004とTFVの混合物を処理し、4日後、p24 ELISA assayで生成されたウイルス量の定量を確認した。
本実験では、AVI−CO−004とFTCを混合した混合物の抗ウイルスの効力を確認した。まず、各100,000個のMT4細胞を48wellプレートに接種してHIV−1p24 0.5ngに該当する量のHIV−1で感染させた。表記された濃度でAVI−CO−004とFTCの混合物を処理し、4日後、p24 ELISA assayで生成されたウイルス量の定量を確認した。
本発明のための実験で得られた結果に基づいて、併用投与によるシナジー効果をさらに検証するため、コルビーの式で計算された理論値と実測値を比較した結果を、下記[表1]〜[表4]に示した。
AVI−CO−004及び2剤のNRTIの併用処理による相乗的HIV抑制能を確認するため、まず、AVI−CO−004単独処理時の抗ウイルス効力を確認した。
AVI−CO−004にNRTI(Nucleoside reverse transcription inhibitor)系の2つの阻害剤であるAZTと3TCをさらに混合する場合、シナジー効果を示すのか検討した。現在のエイズ治療の標準治療法が、2剤のNRTIに1剤の追加薬剤を併用しているので、NRTI系の基底療法を選択した。AZT/3TCは、承認されたエイズ治療剤であるコンビビル製剤の組成である。AZTと3TCの使用濃度は、細胞の予備実験で確認されたAZT(ジドブジン)のIC50の1/2または1/4に相当する濃度を基準に、実際のコンビビル医薬品のフォーミュレーション比率(ratio)に基づいて選択した。
AVI−CO−004にさらに他のNRTI系の2つの阻害剤TFVとFTCをさらに混合する場合、シナジー効果を示すのか検討した。TFV/FTCは、承認されたエイズ治療剤であるツルバダ製剤の組成である。
AVI−CO−004単独処理後に生成されたウイルスの再感染力を確認するために実施例2で得られたウイルスを健康なT細胞に同量(same particles)で感染させた。健康なMT4細胞1×l05cellsを48wellプレートに接種し、p24 2.5ngに該当する同量のHIV−1で感染させた。48時間後、蛍光顕微鏡を用いてGFPの発現によりウイルスの感染力の程度を確認し、定量化のために蛍光活性化セルソーター(FACS)を用いて、ウイルスに再感染したGFP陽性細胞を計数して表記し(図9A)、グラフ化した(図9B)。
AVI−CO−004単独処理とAVI−CO−004/AZT/3TCまたはAVI−CO−004/TFV/FTC併用処理後に生成されたウイルスの感染力を比較するため、実施例2の併用処理後に生成されたウイルスを阻害剤を処理しない対照群と同量(same particle)で定量して、健康なT細胞に再感染させた。
細胞毒性試験は、生きている細胞のATP生成程度を測定することを基盤として行った。各5,000個のMT4細胞または1,000個の293T細胞を96wellプレートに接種し、表記された濃度の治療剤を処理した。併用処理の5日後、CellTiter−Glo reagent kit(Promega社)の実験マニュアルによって行った。Cell lysis後、生きている細胞のATPとGlo reagent物質が反応してluminescence(発光)が生成される。生きている細胞の指標であるLuminescence(発光)の測定は、Molecular Device社のluminescence microplate readerを用いて測定した。
本実験では、AVI−CO−004及びAZTと3TCをさらに混合する場合、細胞毒性を示すのか検討した。
本実験では、AVI−CO−004及びTFVとFTCをさらに混合する場合、細胞毒性を示すのか検討した。
Claims (13)
- 前記ヌクレオシド逆転写酵素阻害剤が、前記化学式1で表される化合物またはその薬学的に許容可能な塩と組み合わされて抗−HIV効果が上昇するものである、請求項1に記載の組成物。
- 前記ヌクレオシド逆転写酵素阻害剤の併用処理時にも、前記化学式1で表される化合物またはその薬学的に許容可能な塩の非感染性ウイルスの生成効果が低下しないものである、請求項1に記載の組成物。
- 前記ヌクレオシド逆転写酵素阻害剤が、アバカビル(ABC)、ジダノシン(ddI)、エムトリシタビン(FTC)、ラミブジン(3TC)、スタブジン(d4T)、テノホビル(TFV)、ジドブジン(AZT)及びその薬学的に許容可能な塩からなる群から選ばれるいずれか1つ以上であるものである、請求項1に記載の組成物。
- 前記ヌクレオシド逆転写酵素阻害剤が、前記化学式1で表される化合物またはその薬学的に許容可能な塩と組み合わされて抗−HIV効果が上昇するものである、請求項5に記載の方法。
- 前記ヌクレオシド逆転写酵素阻害剤の併用処理時にも、前記化学式1で表される化合物またはその薬学的に許容可能な塩の非感染性ウイルスの生成効果が低下しないものである、請求項5に記載の方法。
- 前記ヌクレオシド逆転写酵素阻害剤が、アバカビル(ABC)、ジダノシン(ddI)、エムトリシタビン(FTC)、ラミブジン(3TC)、スタブジン(d4T)、テノホビル(TFV)、ジドブジン(AZT)及びその薬学的に許容可能な塩からなる群から選ばれるいずれか1つ以上であるものである、請求項5に記載の方法。
- 前記記載された化学式1の化合物またはその薬学的に許容可能な塩を1つ以上のヌクレオシド逆転写酵素阻害剤と同時に、または連続的に投与するものである、請求項5に記載の方法。
- 下記化学式1で表される化合物またはその薬学的に許容可能な塩と、ヌクレオシド逆転写酵素阻害剤(Nucleoside reverse transcription inhibitor、NRTI)を含む組成物のAIDSの予防または治療のための使用。
- 前記ヌクレオシド逆転写酵素阻害剤が、前記化学式1で表される化合物またはその薬学的に許容可能な塩と組み合わされて抗−HIV効果が上昇するものである、請求項10に記載の使用。
- 前記ヌクレオシド逆転写酵素阻害剤の併用処理時にも、前記化学式1で表される化合物またはその薬学的に許容可能な塩の非感染性ウイルスの生成効果が低下しないものである、請求項10に記載の使用。
- 前記ヌクレオシド逆転写酵素阻害剤が、アバカビル(ABC)、ジダノシン(ddI)、エムトリシタビン(FTC)、ラミブジン(3TC)、スタブジン(d4T)、テノホビル(TFV)、ジドブジン(AZT)及びその薬学的に許容可能な塩からなる群から選ばれるいずれか1つ以上であるものである、請求項10に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2018-0056007 | 2018-05-16 | ||
KR1020180056007A KR101893988B1 (ko) | 2018-05-16 | 2018-05-16 | 로다닌 유도체를 함유하는 aids 예방 또는 치료용 약학 조성물 |
PCT/KR2019/004855 WO2019221414A1 (ko) | 2018-05-16 | 2019-04-23 | 로다닌 유도체를 함유하는 aids 예방 또는 치료용 약학 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2021531239A true JP2021531239A (ja) | 2021-11-18 |
Family
ID=63407923
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020564362A Pending JP2021531239A (ja) | 2018-05-16 | 2019-04-23 | ロダニン誘導体を含むaidsの予防または治療用薬学組成物 |
Country Status (7)
Country | Link |
---|---|
US (2) | US10821101B2 (ja) |
EP (1) | EP3795155A4 (ja) |
JP (1) | JP2021531239A (ja) |
KR (1) | KR101893988B1 (ja) |
CN (1) | CN112203655A (ja) |
WO (1) | WO2019221414A1 (ja) |
ZA (1) | ZA202007616B (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101893988B1 (ko) * | 2018-05-16 | 2018-08-31 | (주)에빅스젠 | 로다닌 유도체를 함유하는 aids 예방 또는 치료용 약학 조성물 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013528646A (ja) * | 2010-06-18 | 2013-07-11 | アヴィックスゲン インク. | 新規なロダニン誘導体、その製造方法、及びそれを有効成分として含有するエイズ(aids)予防又は治療用薬学組成物 |
WO2015035003A1 (en) * | 2013-09-05 | 2015-03-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Thioether prodrug compositions as anti-hiv and anti-retroviral agents |
JP2021532144A (ja) * | 2018-07-25 | 2021-11-25 | アヴィックスジェン・インコーポレイテッド | ロダニン誘導体を有効成分として含む骨関節炎の予防、改善または治療用薬学的組成物 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6706729B1 (en) * | 1998-06-19 | 2004-03-16 | The United States Of America As Represented By The Department Of Health And Human Services | Thiolesters and uses thereof |
EP1128832A4 (en) * | 1998-08-21 | 2003-03-05 | Viropharma Inc | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS AND RELATED DISEASES |
JP2003252794A (ja) * | 2002-03-01 | 2003-09-10 | Ono Pharmaceut Co Ltd | アルドース還元酵素阻害剤を有効成分として含有するアポトーシス抑制剤 |
AU2004260630B2 (en) * | 2003-02-19 | 2009-12-10 | Masanori Baba | Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections |
RU2007136996A (ru) * | 2005-03-07 | 2009-04-20 | Адвентркс Фармасьютикалз, Инк. (Us) | ПРИМЕНЕНИЕ ТИОФОСФОНОМУРАВЬИНОЙ КИСЛОТЫ И NRTIs ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ |
JP2011502998A (ja) * | 2007-11-01 | 2011-01-27 | ザ ユーエイビー リサーチ ファウンデイション | ウイルス感染の治療および予防 |
KR20180056007A (ko) | 2016-11-17 | 2018-05-28 | 현대 파워텍 주식회사 | 피니언 샤프트 및 이를 구비하는 구동 장치 |
KR101893988B1 (ko) * | 2018-05-16 | 2018-08-31 | (주)에빅스젠 | 로다닌 유도체를 함유하는 aids 예방 또는 치료용 약학 조성물 |
-
2018
- 2018-05-16 KR KR1020180056007A patent/KR101893988B1/ko active IP Right Grant
-
2019
- 2019-04-23 JP JP2020564362A patent/JP2021531239A/ja active Pending
- 2019-04-23 WO PCT/KR2019/004855 patent/WO2019221414A1/ko unknown
- 2019-04-23 CN CN201980032859.1A patent/CN112203655A/zh active Pending
- 2019-04-23 EP EP19804509.8A patent/EP3795155A4/en not_active Withdrawn
- 2019-08-29 US US16/555,998 patent/US10821101B2/en active Active
-
2020
- 2020-09-17 US US17/024,255 patent/US11141407B2/en active Active
- 2020-12-07 ZA ZA2020/07616A patent/ZA202007616B/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013528646A (ja) * | 2010-06-18 | 2013-07-11 | アヴィックスゲン インク. | 新規なロダニン誘導体、その製造方法、及びそれを有効成分として含有するエイズ(aids)予防又は治療用薬学組成物 |
WO2015035003A1 (en) * | 2013-09-05 | 2015-03-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Thioether prodrug compositions as anti-hiv and anti-retroviral agents |
JP2021532144A (ja) * | 2018-07-25 | 2021-11-25 | アヴィックスジェン・インコーポレイテッド | ロダニン誘導体を有効成分として含む骨関節炎の予防、改善または治療用薬学的組成物 |
Non-Patent Citations (2)
Title |
---|
ANTIVIRAL RESEARCH, vol. 134, JPN6022022531, 2016, pages 216 - 225, ISSN: 0005086963 * |
RETROVIROLOGY, vol. 12:90, JPN6022022532, 2015, pages 1 - 15, ISSN: 0005086962 * |
Also Published As
Publication number | Publication date |
---|---|
EP3795155A4 (en) | 2022-01-26 |
US20210000802A1 (en) | 2021-01-07 |
CN112203655A (zh) | 2021-01-08 |
KR101893988B1 (ko) | 2018-08-31 |
WO2019221414A1 (ko) | 2019-11-21 |
ZA202007616B (en) | 2021-08-25 |
EP3795155A1 (en) | 2021-03-24 |
US20190388399A1 (en) | 2019-12-26 |
US11141407B2 (en) | 2021-10-12 |
US10821101B2 (en) | 2020-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5231242B2 (ja) | ヌクレオチド及びヌクレオシド系逆転写酵素阻害剤(テノホビル及びラミブジン)を剤形の異なる部分に含む医薬組合せ | |
JP4847441B2 (ja) | Hiv感染の治療方法 | |
CN106714800A (zh) | 用于治疗hiv的toll样受体调节剂 | |
EA032868B1 (ru) | Комбинация для лечения вич-инфекции | |
JP2016519166A (ja) | Hiv感染症を処置するための方法および組成物 | |
JP2023524290A (ja) | Sars-cov-2の治療のための方法及び組成物 | |
CA2793749C (fr) | Nouveaux schemas d'administration de multitherapies utiles pour le traitement des personnes affectees par le virus de l'immunodeficience humaine (vih) | |
EP2501386B1 (fr) | Quadritherapie utile pour le traitement des personnes atteintes du virus de l'immunodéficience humaine (vih) | |
TW201127384A (en) | Therapeutic combination comprising a Cdc7 inhibitor and an antineoplastic agent | |
JP2021531239A (ja) | ロダニン誘導体を含むaidsの予防または治療用薬学組成物 | |
TW201919630A (zh) | 用於治療hiv感染及aids之療程 | |
WO2018005914A1 (en) | Regimens and compositions for treating hiv infections and aids | |
US11191763B2 (en) | HIV post-exposure prophylaxis | |
US9713622B2 (en) | Schedules for administering combination therapies useful for treating persons afflicted with the human immunodeficiency virus (HIV) | |
DE60027691T2 (de) | Beta-D-2',3'-didehydro-2',3'-didesoxy-5-fluorcytidin für die Verwendung in der Behandlung von HIV Infektionen | |
AU2017268621C1 (en) | Antiviral therapy | |
US20200147092A1 (en) | Regimens for treating hiv infections and aids | |
WO2019110563A1 (en) | Treatment of rsv with combination product | |
JP2020530024A (ja) | 組み合わせ並びにその使用及び治療 | |
Ekmekyapar et al. | Antiviral Drugs and Their Toxicities | |
EP1931358A1 (en) | Pharmaceutical combinations containing lamivudine, stavudine and nevirapine | |
Stanic et al. | Review of antiretroviral agents for the treatment of HIV infection. | |
KR20070114806A (ko) | 바이러스 감염 치료에의 티오포스포노포름산 및 nrti의용도 | |
JP2020529461A (ja) | 組み合わせ並びにその使用及び治療 | |
JP2019528304A (ja) | 組み合わせ並びにその使用及び治療 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210510 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220607 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220803 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221115 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230620 |